| 词条 | Natera |
| 释义 |
| name = Natera | logo = File:Natera logo.gif | type = Public | traded_as = {{NASDAQ|NTRA}} Russell 2000 Component | location = San Carlos, California | key_people = Steve Chapman (CEO) Jonathan Sheena (CTO) Matthew Rabinowitz (Executive Chairman) |revenue= {{Profit}} US$ 210.9 million (2017) | industry = Genetic testing | homepage = www.natera.com }}Natera (previously Gene Security Network) is a genetic testing company that operates a CLIA-certified laboratory in San Carlos, California.[1] The company specializes in analyzing microscopic quantities of DNA for reproductive health indications to provide preconception and prenatal genetic testing services primarily to OBGYN physicians and in vitro fertilization centers.[2] In early 2013, the company launched Panorama, a non-invasive prenatal test for pregnant women that screens for the most common chromosomal anomalies in a fetus as early as nine weeks of gestation.[3] Other services include tests for preimplantation genetic diagnosis (PGD) and miscarriage testing to determine the cause of the loss of the pregnancy.[4] A non-invasive paternity test based on Natera’s technology, was brought to market in August 2011 through a partnership with DNA Diagnostics Center (DDC), which holds a license to the technology in the United States.[5] In July 2015, Natera conducted an initial public offering of common stock at a price of $18.00 per share. The shares trade on the Nasdaq Global Select Market under the symbol "NTRA."[6] Panorama TestNatera launched a non-invasive prenatal test (NIPT) in February 2013 called Panorama that uses an advanced bioinformatics-based algorithm to analyze the cell-free fetal DNA that is found in the mother’s blood. Panorama detects chromosome abnormalities, including Trisomy 21, the cause of Down syndrome, Trisomy 18, the cause of Edwards syndrome, Trisomy 13, the cause of Patau syndrome, sex chromosome abnormalities, triploidy and certain microdeletions as early as the first trimester of pregnancy.[7][8][9] A clinical study evaluating Natera’s NIPT is funded by the National Institutes of Health and is currently ongoing. CompetitionCompanies also offering non-invasive prenatal genetic testing include Sequenom, Ariosa (Harmony Prenatal Test), Ravgen, and Verinata Health. Other companies and universities that are working towards developing non-invasive prenatal testing include Stanford University,[10] Fluidigm and Ikonisys. References1. ^Prenatal testing company Natera raises $20M (San Francisco Business Times) 2. ^One-on-One with Natera founder Jonathan Sheena (San Francisco Business Times) 3. ^Natera Launches Noninvasive Prenatal Test; Quest to Offer in Limited Areas by March, Nationwide in April (GenomeWeb) 4. ^{{cite web|url=http://www.xconomy.com/san-francisco/2014/02/12/miscarriage-mysteries-create-new-market-for-natera/|title=Miscarriage Mysteries Create New Market for Natera - Xconomy|date=12 February 2014|publisher=}} 5. ^{{cite web|url=https://www.bloomberg.com/news/articles/2011-12-09/gsn-races-to-improve-prenatal-tests-for-genetic-conditions|title=GSN Races to Improve Prenatal Tests for Genetic Conditions|publisher=|via=www.bloomberg.com}} 6. ^{{Cite web|url=https://www.nasdaq.com/symbol/ntra/real-time|title=Natera, Inc. Common Stock (NTRA) Real-Time Stock Quote - NASDAQ.com|website=www.nasdaq.com|language=en-us|access-date=2018-06-28}} 7. ^{{cite web|url=https://www.bloomberg.com/news/articles/2013-04-25/innovator-matt-rabinowitz-sifts-gene-data-for-healthy-pregnancies|title=Innovator: Matt Rabinowitz Sifts Gene Data for Healthy Pregnancies|date=26 April 2013|publisher=|via=www.bloomberg.com}} 8. ^{{cite journal |vauthors=Nicolaides KH, Syngelaki A, Gil MM, Quezada MS, Zinevich Y |title=Prenatal Detection of Fetal Triploidy from Cell-Free DNA Testing in Maternal Blood |journal=Fetal Diagnosis and Therapy |volume= 35|issue= 3|pages= 212–7|date=October 2013 |pmid=24135152 |doi=10.1159/000355655}} 9. ^{{cite journal|url=http://www.nature.com/news/prenatal-screening-companies-expand-scope-of-dna-tests-1.14807|title=Prenatal-screening companies expand scope of DNA tests|journal=Nature|first=Erika|last=Check Hayden|date=6 March 2014|publisher=|volume=507|issue=7490|pages=19–19|doi=10.1038/507019a}} 10. ^{{cite web|url=http://www.bionews.org.uk/page_13538.asp |title=Non-invasive prenatal test for Down's syndrome developed |publisher=BioNews }} External links
4 : Health care companies based in California|Companies based in San Carlos, California|Companies listed on NASDAQ|2015 initial public offerings |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。